Sava Reports World-First 10-Day Clinical Evidence for Continuous Glucose Monitoring
•February 10, 2026
0
Why It Matters
The validation shows minimally invasive microsensors can match conventional CGM performance over extended wear, potentially expanding adoption beyond the current 1% of diabetics using CGMs and lowering barriers to continuous health monitoring. This breakthrough paves the way for scalable, multi‑biomarker platforms that could shift healthcare toward proactive, real‑time disease management.
Key Takeaways
- •10‑day CGM evidence from 46 diabetic participants.
- •Microsensor MARD within 0.8% of commercial CGM.
- •Sensor length 10× shorter, less tissue disruption.
- •Accuracy drift only ~1.5% over ten days.
- •Platform aims multi‑analyte monitoring, commercial 2027.
Pulse Analysis
Diabetes remains a global health challenge, with nearly 590 million adults affected in 2024 and projections soaring to 853 million by 2050. Continuous glucose monitors (CGMs) have reshaped diabetes care, yet adoption lags at roughly 1% of patients, constrained by invasiveness, cost, and wear‑time limitations. Sava Technologies’ 10‑day microsensor study directly addresses these pain points, offering a less intrusive alternative that could accelerate CGM uptake and stimulate broader market growth.
The core of Sava’s advantage lies in its microsensor architecture, which replaces the traditional 5‑10 mm filament with a sensor an order of magnitude shorter. This design minimizes skin disruption while still accessing interstitial fluid, delivering accuracy comparable to established CGMs—evidenced by a MARD gap of only 0.8 percentage points and a modest 1.5 % drift over ten days. Such performance metrics not only satisfy clinical benchmarks but also simplify regulatory pathways, positioning Sava for a pivotal 2026 trial and eventual 2027 commercial launch.
Beyond glucose, Sava envisions a modular platform capable of real‑time monitoring of multiple biomarkers, turning a single‑use diabetes tool into a versatile health‑data engine. With $32 million raised and manufacturing scaling underway, the company is poised to capitalize on the $12 billion CGM market while opening new revenue streams in preventive health. If successful, this technology could catalyze a shift from reactive testing to continuous molecular insight, reshaping how chronic diseases are managed at scale.
Sava reports world-first 10-day clinical evidence for continuous glucose monitoring
Sava Technologies Announces World’s First 10‑Day Clinical Evidence for Continuous Glucose Monitoring via Proprietary Microsensor Technology
Sava Technologies, the London‑based startup pioneering real‑time molecular health monitoring, reports the world’s first 10‑day clinical evidence for continuous glucose monitoring via its proprietary microsensor technology.
The company has successfully completed an independent clinical study, enrolling 46 participants with Type 1 and insulin‑dependent Type 2 diabetes across sites in Oxford and Cambridge with study design informed by clinicians. The study demonstrated reliable glucose measurement using Sava’s proprietary microsensor technology over the 10‑day wear period.
Sava conducted a clinical study enabling a head‑to‑head comparison with a continuous glucose monitor (CGM) globally. Each participant simultaneously wore a Sava microsensor and the comparator CGM, with both systems benchmarked against a YSI reference. MARD was calculated for each device relative to YSI, and the results show comparable performance over the full 10‑day wear period, with a MARD difference between Sava and the commercial CGM of ~0.8 percentage points.
Traditional CGMs rely on a filament‑based sensor, inserted 5 mm‑10 mm into the skin, using a hypodermic needle. Sava’s proprietary microsensor technology replaces conventional filaments with miniaturised sensors approximately 10 times shorter, reducing skin tissue disruption while maintaining access to interstitial fluid.
A key consideration with minimally invasive sensors is whether performance can be sustained over multiple days. Preliminary results indicate strong 10‑day wear performance, with accuracy drifting by only ~1.5 percentage points over the wear period. Overall, this study validates the sustained accuracy, extended wear, and real‑world reliability of Sava’s microsensing platform.
Rising chronic disease, escalating healthcare costs, and a shift toward proactive health management are driving the need for less invasive sensing technologies, and diabetes is the first frontier. Approximately 589 million adults (20‑79 years) were living with diabetes globally in 2024, a figure projected to rise to 853 million by 2050. Today, just 1 % of people with diabetes use CGMs, yet this group generates almost $12 B in annual sales, growing 10 % year‑on‑year.
Sava co‑founder and co‑CEO Renato Circi comments: “Microsensors were long treated as a ‘future promise’. Powerful in theory but unproven in practice. That phase is now over. We now know microsensing works, and the focus has shifted from possibility to scale.”
While glucose is the first application, Sava’s vision is to build a modular, multi‑analyte sensing platform capable of detecting additional molecules, enabling minimally invasive, real‑time monitoring of multiple biomarkers. By establishing clinical evidence for minimally invasive sensing in continuous glucose monitoring, this trial validates Sava’s approach to evolving microsensor‑based monitoring from a diabetes optimisation tool into a foundational platform for continuous molecular insight, supporting a broader shift from reactive testing to preventative, continuous healthcare at scale.
Sava co‑founder and co‑CEO Rafaël Michali comments: “Proving glucose was the first step. With that foundation in place, we can now expand into new analytes, unlocking entirely new applications built on the same technological foundation.”
Following this milestone, Sava is progressing toward a pivotal clinical study in 2026 in preparation for future regulatory submissions, alongside scaling manufacturing capabilities for its platform. With $32 m raised from global investors to date, the company is targeting 2027 for commercial availability.
0
Comments
Want to join the conversation?
Loading comments...